Zhitong Finance App News, Yuandong Biotech (688513.SH) announced that the company and its wholly-owned subsidiary Chengdu Shuode Pharmaceutical Co., Ltd. participated in the bidding process for the 12th batch of centralized national drug procurement organized by the Joint Procurement Office of the State Organization on July 31, 2026. According to the “Announcement on the Proposed Selection Results for the 12th Batch of Centralized Volume Procurement of National Organization Drugs” issued by the Joint Procurement Office that night, the company and its wholly-owned subsidiaries plan to select nicardipine hydrochloride injections and bisoprolol amlodipine tablets for this centralized procurement.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.